5-MeO-DMT: Throwing the Grenade into the Lake of Your Subconscious Mind with Tandava Retreats
Similar Posts
Suing the City of Oakland for Mushroom Raid with Dave Hodges
In this episode, Dave speaks to Dennis Walker about how Oakland PD raided his church and confiscated $200,000 worth of sacraments.
Andrew Yang Supports LEGALIZING PSILOCYBIN in New York (But Can He Do It?)
Hello psychedelic investors! Today’s episode is a bit different yet still relevant to all of us invested in the psychedelic industry!
To summarize,
Andrew Yang comes out Hard against the war on drugs and for legalizing psilocybin. He says “The war on drugs has been a war on people”.
Specifically, Andrew Yang calls out the criminalization of opioid use, saying big pharma has gotten these people addicted while “generating billions of dollars of blood money”, and then we throw people in jail for the pharma industries failures.
This is, in Yang’s eyes, not a criminal problem, but a public health problem.
If people are addicted to something, don’t throw them in jail, get them the help that they need to treat an illness that in many cases was caused by billionaire pharma companies.
How will Andrew Yang create a de facto decriminalization?
He would instruct the DA not to prosecute for possession charges.
Its that simple.
Finally he talks about how he is for the legalization of psilocybin and open to legalize other substances.
Yang is calling for decriminalizing the use of all drugs, AND to legalize psilocybin..
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
For any collaborations, you can reach us on our email
email: thepsychedelicinvestor@gmail.com
If you are thinking of joining Benzinga Pro, why not use our link, and we will both get a discount!
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#AndrewYang #AndrewYangMayor #AndrewYangDebate
Interview With Sacha Hebbert
Mind Cure Health’s Senior Product and Marketing Manager, Sacha Hebbert, talks about the company’s recent launch of its product sales division.
MindMed: What Does The Future Hold? ( MMED/ MNMD )
Hey guys! Today, we’ll cover Part 2 of our discussion on MindMed’s (MMED / MNMD / MMQ) conference call.
In the previous episode, we talked about the progress MindMed has made up until this point, MindMed’s mission, talent Acquisition, and the progress of their clinical trials.
In today’s episode, we will take a more futuristic approach and examine the future plans discussed in MindMed’s Q1 conference call. We will cover topics such as:
A. Where is MindMed going?
B. What is MindMed 2.0?
C. What will MindMed in 3 years time look like as compared to now?
Over the next several years, we expect 4 transformations to occur.
1. MindMed’s transition to a tech company, from a pharmaceuticals company;
2. The shift from classic psychedelics like LSD to “next generation” patent protected substances;
3. Reorientation away from one size fits all medical solutions towards personalized medicine;
4. Finding Partnerships with major pharmaceutical companies.
Timestamps:
0:00 – Intro
2:16 – MindMed transitioning to a tech company
7:14 -Next-gen shift
12:11 – Personalized medicine
13:59 – Partnerships
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindMedstock
Can TRYP Therapeutics Treat Chronic Pain and Eating Disorders With Psychedelics? (TRYP / TRYF)
In today’s episode, we’ll be interviewing CEO and Chairman of TRYP Therapeutics, Greg Mckee. Thus far, this is one of the most informative conversations I’ve had the pleasure of having about the psychedelic industry, the different segments that could be simultaneously tackled, the challenges and opportunities for many of the players in this industry and much more.
I hope you stay till the end and are able to get some value from this discussion.
TRYP Therapeutics (CSE: TRYP) (OTC: TRYPF), is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Some of the diseases TRYP is addressing are: eating disorders and fibromyalgia (chronic widespread pain) .
TRYP intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803.
Timestamps:
0:00 – Intro
0:40 – TRYP’s mission and Greg Mckee’s personal involvement
2:59 – Expanding on TRYP’s main molecules: TRP 8802 and TRP 8803
8:18 – Expanding on TRYP’s flagship programs: Fibromyalgia and Eating Disorder
14:29 – Clinical trial progress and anticipated start of Phase IIa trials
18:26 – Anticipated commercialization timelines
21:34 – TRYP Therapeutics’ competitive advantage
27:22 – Expected relationship with the traditional pharmaceuticals industry and potential partnerships
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Pertinent links:
Tryp Therapeutics’ Mission:
https://tryptherapeutics.com/
Tryp’s pipeline progress:
https://tryptherapeutics.com/pipeline/
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (TRYP) via digital communications. We have been paid ($1000) .
https://tryptherapeutics.com/
CSE: TRYP | OTC: TRYPF
#TRYP #TrypTherapeutics #TrypStock